title: Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.
abstract: BACKGROUND
  Patients with nonvalvular atrial fibrillation (AF) have an increased risk of stroke and other vascular events.
  
  
  OBJECTIVE
  To compare the risk of vascular and bleeding events in patients with nonvalvular AF treated with vitamin K -inhibiting oral anticoagulants or acetylsalicylic acid (aspirin).
  
  
  METHODS
  Pooled analysis of patient-level data from 6 published, randomized clinical trials.
  
  
  METHODS
  A total of 4052 patients with AF randomly assigned to receive therapeutic doses of oral anticoagulant or aspirin with or without low-dose oral anticoagulants.
  
  
  METHODS
  Ischemic and hemorrhagic stroke, other cardiovascular events, all-cause death, and major bleeding events. Person-year incidence rates were calculated to provide crude comparisons. Relative efficacy was assessed using proportional hazards modeling stratified by study. The variation of the oral anticoagulant's relative effect by pertinent patient factors was explored with interaction terms. All analyses were conducted using the intention-to-treat principle.
  
  
  RESULTS
  Patients receiving oral anticoagulant and aspirin were balanced for important prognostic factors. There was no significant heterogeneity between trials in the relative efficacy of oral anticoagulant vs aspirin for any outcome. Patients receiving oral anticoagulant were significantly less likely to experience any stroke (2.4 vs 4.5 events per 100 patient-years; hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.43-0.71), ischemic stroke (HR, 0.48; 95% CI, 0.37-0.63), or cardiovascular events (HR, 0.71; 95% CI, 0.59-0.85) but were more likely to experience major bleeding (2.2 vs 1.3 events per 100 patient-years; HR, 1.71; 95% CI, 1.21-2.41). The reduction in ischemic stroke risk was similar in patients with paroxysmal AF (1.5 vs 4.7 events per 100 patient-years; HR, 0.32; 95% CI, 0.16-0.61; P<.001). Treating 1000 patients with AF for 1 year with oral anticoagulant rather than aspirin would prevent 23 ischemic strokes while causing 9 additional major bleeds. Overall all-cause survival did not differ but appeared to improve for oral anticoagulant patients 3 years after therapy was started.
  
  
  CONCLUSIONS
  Compared with aspirin, oral anticoagulant significantly decreases the risk of all strokes, ischemic strokes, and cardiovascular events for patients with nonvalvular chronic or paroxysmal AF but modestly increases the absolute risk of major bleeding. The balance of benefits and risks varies by patient subgroup.
authors.affiliation: Clinical Epidemiology Unit, Ottawa Health Research Institute, F-6, Ottawa Hospital, Civic Campus, 1053 Carling Ave, Ottawa, Ontario, Canada K1Y 4E9. carlv@ohri.ca
authors.forename: Carl
authors.initials: C
authors.lastname: van Walraven
authors.forename: Robert G
authors.initials: RG
authors.lastname: Hart
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Singer
authors.forename: Andreas
authors.initials: A
authors.lastname: Laupacis
authors.forename: Stuart
authors.initials: S
authors.lastname: Connolly
authors.forename: Palle
authors.initials: P
authors.lastname: Petersen
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Koudstaal
authors.forename: Yuchiao
authors.initials: Y
authors.lastname: Chang
authors.forename: Beppie
authors.initials: B
authors.lastname: Hellemons
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006470:Hemorrhage / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control; D016019:Survival Analysis; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin